Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic

09/19/22 • 28 min

For biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our investor base strong and interested? Is now the right time? The Nordic Markets offer some distinct advantages at the earlier stage, and also offer new possibilities for US companies to list abroad. And although the specific logistical and mechanical aspects are exceedingly important, at the end of the day, the decision to do something like this is predicated on an amalgam of strategic decisions.

In this episode Back Bay Life Science Advisors and Nasdaq outline best practices for companies considering a public listing, including:

Steps in best practice strategy in an increasingly complex market
Advantages of listing with a smaller listing threshold market
Similarities and differences between Nasdaq US and Nasdaq Nordic markets
The strategic change and new dual listing option for US companies
The unique way retail participation makes up a large portion of the Nasdaq Nordic market (>25% of trades come in from retail)
Differences in support for emerging companies, Nordic v. US markets

Jonathan Gertler is CEO of Back Bay Life Science Advisors and Managing Partner at Bioventures Medtech Funds. Maria Groschopp Dellwik is Nasdaq’s Head of Strategy and Business Development for Global Listing Services in the Nordics, where she manages new offerings and key strategic change initiatives to improve listing offerings and the Swedish capital market.

Download “Preparing for a Public Listing: Best Practices for Biopharma, Medtech and
Healthtech Companies” from Back Bay Life Science Advisors and Nasdaq
https://bblsa.com/investment-banking-1

In this episode Back Bay Life Science Advisors and Nasdaq outline best practices for companies considering a public listing, including:

Steps in best practice strategy in an increasingly complex market
Advantages of listing with a smaller listing threshold market
Similarities and differences between Nasdaq US and Nasdaq Nordic markets
The strategic change and new dual listing option for US companies
The unique way retail participation makes up a large portion of the Nasdaq Nordic market (>25% of trades come in from retail)
Differences in support for emerging companies, Nordic v. US markets

Download “Preparing for a Public Listing: Best Practices for Biopharma, Medtech and
Healthtech Companies” from Back Bay Life Science Advisors and Nasdaq
https://bblsa.com/investment-banking-1

Previous Episode

The Promising Field of Targeted Protein Degraders (TPDs)

with Back Bay Life Science Advisors’ Dr. Peter Bak and Dr. Mavra Nasir

Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmakers outlining the current state of play in the promising field of protein degradation. In this episode, Dr. Nasir sits down with Peter Bak to discuss the recent surge of venture funding and partnerships surrounding TPDs.

Read Dr. Nasir's article "From drug target inhibition to degradation: a TACtical strategy" here.

Topics in this podcast include:

An intro into targeted protein degradation (TPDs) and proteolysis-targeting chimeras (PROTACs)
Industry advantages of TPDs vs. traditional antibodies
Biopharma and VC's growing interest in molecular glues
Commercial hurdles ahead in this space
How TPD companies can differentiate, from a pipeline and breadth of opportunities to select an indication, communicate to investors and drive value

If you have a question about life sciences development, submit it here. We may feature it on an upcoming episode.

Thanks for joining us!

Mavra Nasir, PhD is a senior consultant at Back Bay Life Science Advisors where she supports strategic engagements across a range of therapeutic areas including rare diseases, hematology/oncology and metabolic diseases for biopharma and MedTech. Dr. Nasir joined Back Bay after receiving her PhD in Quantitative Biomedical Sciences from Dartmouth College.

Next Episode

Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022

In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. From CRISPR and gene editing advancement to cross-species organ transplantation and the latest in the evolving regulatory and reimbursement landscape, these stories captivated us and continue to herald progress in health and human care.

Podcast experts include Brendan Wang, Christian Thienel and Peter Bak, with special thanks to Micheka Fenelon.